AU Patent

AU2024205772A1 — Pharmaceutical compositions comprising meloxicam

Assigned to Axsome Therapeutics Inc · Expires 2024-09-05 · 2y expired

What this patent protects

A method of treating migraine, comprising orally administering a pharmaceutical composition to a human being who is suffering from migraine pain, wherein the pharmaceutical composition is in a solid dosage form comprising a drug such as a triptan (e.g. rizatriptan) and/or an NS…

USPTO Abstract

A method of treating migraine, comprising orally administering a pharmaceutical composition to a human being who is suffering from migraine pain, wherein the pharmaceutical composition is in a solid dosage form comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024205772A1
Jurisdiction
AU
Classification
Expires
2024-09-05
Drug substance claim
No
Drug product claim
No
Assignee
Axsome Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.